Chen and Mellman [25] divided the tumor immune microenvironment into three types: immune-inflamed, immune desert-type, and immune excluded-type, by analyzing the immunohistochemical results of a large number of tumor specimens before treatment and combining these results with their overall reaction to PD-L1/PD-1 targeted inhibitors. The gene discussed is PDCD1; the disease is neoplasm.